anti-gp100:154-162 TCR-engineered lymphocytes
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for anti-gp100:154-162 TCR-engineered lymphocytes, covering 2012-12-04 to 2012-12-04. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes [Phase 2]